deltatrials
Completed PHASE3 NCT00257205

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

A Phase 3, Open Label, Randomized, Comparative Study Of CP-675,206 And Either Dacarbazine Or Temozolomide In Patients With Advanced Melanoma

Sponsor: AstraZeneca

Conditions Melanoma
Interventions CP-675,206 dacarbazine temozolomide
Updated 8 times since 2017 Last updated: Jun 25, 2012 Started: Mar 31, 2006 Primary completion: Aug 31, 2010 Completion: Aug 31, 2010

This PHASE3 trial investigates Melanoma and is currently completed. AstraZeneca leads this study, which shows 8 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE3

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia, Albany, United States, Amsterdam, Netherlands, Athens, Greece, Aurora, United States, Bakersfield, United States, Baltimore, United States, Barcelona, Spain, Beech Grove, United States, Berlin, Germany and 122 more location s